Improving together the medical learning about NASH to better address its causes and consequences and serve patients.
The NASH Education ProgramTM defines and drives initiatives in collaboration with an independent scientific committee² composed of four international key opinion leaders, well-known and respected in the field, with a footprint in both hepatic and metabolic diseases, and a strong presence in the United States as well as in Europe.
The objective of this public health initiative is to place the practitioner and the patient at the heart of tomorrow's awareness and education actions. It aims at producing essential and relevant scientific and medical knowledge, and at disseminating it towards targeted audiences:
- > All physician specialties, going beyond hepato-gastroenterology, i.e. including diabetologists, endocrinologists, obesity specialists, cardiologists, OB-GYN and general practitioners who will all have a key role to play in the clinical management of NASH patients;
- > Patients and their families, but also individuals at risk, who all need to understand causes, mechanisms and consequences of the disease, to fully appreciate the importance of an early diagnosis and a treatment well-suited to their condition.
- 100,000,000 Americans have a fatty liver. Most don't know it.
- 20,000,000 will develop liver fibrosis disease or NAFLD (nonalcoholic fatty liver disease) as a result.
- 2,000,000 million will progress to liver cirrhosis or NASH (nonalcoholic steatohepatitis) and end stage liver failure.
- Some will be lucky enough to be listed for a transplant, the only cure for late stage liver disease, but 30% of those listed will die waiting. Death by liver failure is long and difficult.
- We want to help you avoid this kind of death by helping you understand how you may be killing yourself slowly. And, what you can do about it.
- If you are already ill, we will do our best to help you with that process.
To improve the diagnosis, treatment & support of Americans with fatty liver, NAFLD or NASH through awareness, education, screening & advocacy.
About NAFLD & NASH
> This short video, from John's Hopkins Medicine, gives a good overview of nonalcoholic fatty liver disease. Dr. Saleh Alqahtani, director of clinical liver research and assistant professor of medicine, answers questions about the causes, symptoms and treatments.
> In this video, brought to you by THE NASH EDUCATION PROGRAM, internationally renowned opinion leaders address NAFLD (nonalcoholic fatty liver disease) and NASH (nonalcoholic steatohepatits) and their challenges.
> This video is fairly technical, but well worth the time to watch. Dr. Stephen Harrison, Hepatologist and international opinion leader in fatty liver disease and NASH, discusses the evolving landscape of fatty liver disease in the United States as well as diagnostic approaches to identify patients at risk for this disease.